Skip to main content

Commercial development of my own research discoveries: The personal stories of former NIH scientists

Thursday, October 11, 2012 — Concurrent Symposia Session IV

Noon – 2:00 p.m.

Balcony A


  • Steven Ferguson, OD
  • Todd Chappell, OD


Long before NCATS, CTSAs and similar programs supporting translational science came to NIH, intramural investigators often fulfilled their vision of achieving the translational product goals for their research by leaving NIH to start or co-found their own companies. By practicing translational science of the "DIY (do-it-yourself) variety" these investigators were able to achieve major personal, scientific and professional goals -- and have both important clinical and economic impacts for their science. In Maryland alone over 50 of the founders of Maryland bioscience/biomedical companies spent some time as intramural investigators. Without this talent from the NIH intramural program, Maryland would not have one of the top concentrations of bioscience/biomedical companies in the country. This mini-symposium will feature presentations from a variety of distinguished former NIH intramural scientists who became company founders and will share the story of their science and passion for bringing it forward for development.

NIH Entrepreneur-in-Residence: Helping scientists determine if their bench discoveries truly do have commercial applications
Todd Chappell, OD

Ariavax: Vaccine immunogens that are small molecules that are covalently conjugated to nanoparticles
Frank Robey, NIDCR

CC Biotech: Using novel counter-current chromatography approaches to purify bio-active synthetic peptides
Martha Knight, NHLBI

GeneDX: Making clinical testing available to people with rare genetic conditions and their families
Sheri Bale, NIAMS

Cytimmune: Colloidal gold-based drug compounds which harness the therapeutic potential of potent anti-cancer agents
Lawrence Tamarkin, NCI

back to top